PE20201495A1 - Compuesto de pirimidina como inhibidor de las janocinasas - Google Patents

Compuesto de pirimidina como inhibidor de las janocinasas

Info

Publication number
PE20201495A1
PE20201495A1 PE2020000414A PE2020000414A PE20201495A1 PE 20201495 A1 PE20201495 A1 PE 20201495A1 PE 2020000414 A PE2020000414 A PE 2020000414A PE 2020000414 A PE2020000414 A PE 2020000414A PE 20201495 A1 PE20201495 A1 PE 20201495A1
Authority
PE
Peru
Prior art keywords
compound
janocinases
inhibitor
pyrimidine compound
amino
Prior art date
Application number
PE2020000414A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Kozak
Ryan Hudson
Gary E L Brandt
Robert Murray Mckinnell
Marta Dabros
Jerry Nzerem
Original Assignee
Theravance Biopharma Randd Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma Randd Ip Llc filed Critical Theravance Biopharma Randd Ip Llc
Publication of PE20201495A1 publication Critical patent/PE20201495A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Dental Preparations (AREA)
PE2020000414A 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de las janocinasas PE20201495A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762577852P 2017-10-27 2017-10-27
PCT/US2018/057682 WO2019084383A1 (en) 2017-10-27 2018-10-26 PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
PE20201495A1 true PE20201495A1 (es) 2020-12-29

Family

ID=64277858

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000414A PE20201495A1 (es) 2017-10-27 2018-10-26 Compuesto de pirimidina como inhibidor de las janocinasas

Country Status (38)

Country Link
US (7) US10308646B2 (https=)
EP (1) EP3672965B1 (https=)
JP (1) JP7218364B2 (https=)
KR (1) KR102613503B1 (https=)
CN (1) CN111247142B (https=)
AR (1) AR113803A1 (https=)
AU (1) AU2018354370B2 (https=)
BR (1) BR112020008015A2 (https=)
CA (1) CA3074034A1 (https=)
CL (1) CL2020001090A1 (https=)
CR (1) CR20200180A (https=)
CU (1) CU24671B1 (https=)
DK (1) DK3672965T3 (https=)
DO (1) DOP2020000083A (https=)
EA (1) EA202091016A1 (https=)
EC (1) ECSP20023795A (https=)
ES (1) ES2932526T3 (https=)
GE (2) GEAP202115340A (https=)
HR (1) HRP20221221T1 (https=)
HU (1) HUE060401T2 (https=)
IL (1) IL274037B2 (https=)
LT (1) LT3672965T (https=)
MA (1) MA49956B1 (https=)
MD (1) MD3672965T2 (https=)
MX (1) MX2020004255A (https=)
NI (1) NI202000032A (https=)
PE (1) PE20201495A1 (https=)
PH (1) PH12020500528A1 (https=)
PL (1) PL3672965T3 (https=)
PT (1) PT3672965T (https=)
RS (1) RS63608B1 (https=)
SG (1) SG11202001706RA (https=)
SI (1) SI3672965T1 (https=)
SM (1) SMT202200409T1 (https=)
TW (1) TWI789446B (https=)
UA (1) UA125130C2 (https=)
WO (1) WO2019084383A1 (https=)
ZA (1) ZA202001641B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001706RA (en) * 2017-10-27 2020-03-30 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor
WO2020108613A1 (zh) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
PL3958969T3 (pl) 2019-04-24 2024-05-20 Theravance Biopharma R&D Ip, Llc Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
TW202106681A (zh) * 2019-04-24 2021-02-16 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑
WO2022027041A1 (en) 2020-07-28 2022-02-03 Arcutis Biotherapeutics, Inc. Topical formulation containing jak inhibitor and laureth-4
CA3190539A1 (en) * 2020-08-26 2022-03-03 William Greenlee Modulators of myc family proto-oncogene protein
WO2022076771A1 (en) * 2020-10-08 2022-04-14 Icahn School Of Medicine At Mount Sinai Compositions for treatment alopecia areata, biomarkers for treatment success, and methods of use thereof
TW202311256A (zh) * 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof
CA3240662A1 (en) 2021-12-15 2023-06-22 Herbert R. Brinkman Stable formulations of shr0302
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
CN115487301B (zh) * 2022-11-08 2023-07-07 四川大学华西医院 Il-13抑制剂在制备延缓或治疗视网膜色素变性的药物中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6989385B2 (en) 2000-12-21 2006-01-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2008525422A (ja) * 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
US20070179125A1 (en) 2005-11-16 2007-08-02 Damien Fraysse Aminopyrimidines useful as kinase inhibitors
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
CN104011050A (zh) 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (https=) * 2014-08-21 2018-03-31
JP2017535520A (ja) * 2014-09-30 2017-11-30 ハンミ・ファイン・ケミカル・カンパニー・リミテッドＨａｎｍｉ Ｆｉｎｅ Ｃｈｅｍｉｃａｌ Ｃｏ．， Ｌｔｄ． 高純度の（ｒ）−９−［２−（ホスホノメトキシ）プロピル］アデニンの製造方法
ES2753159T3 (es) 2015-05-28 2020-04-07 Theravance Biopharma R&D Ip Llc Compuestos de naftiridina como inhibidores de quinasa JAK
JP2018527362A (ja) * 2015-09-11 2018-09-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換されたヘテロアリール化合物および使用方法
CA3020506A1 (en) 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
SG11202001706RA (en) 2017-10-27 2020-03-30 Theravance Biopharma R&D Ip Llc Pyrimidine compound as jak kinase inhibitor
PL3958969T3 (pl) 2019-04-24 2024-05-20 Theravance Biopharma R&D Ip, Llc Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
TW202106681A (zh) 2019-04-24 2021-02-16 美商施萬生物製藥研發Ｉｐ有限責任公司 用於治療皮膚疾病之嘧啶jak抑制劑

Also Published As

Publication number Publication date
ZA202001641B (en) 2021-04-28
MA49956B1 (fr) 2022-11-30
US20190127364A1 (en) 2019-05-02
PT3672965T (pt) 2022-09-29
EP3672965B1 (en) 2022-09-07
US20200369660A1 (en) 2020-11-26
US10988470B2 (en) 2021-04-27
PH12020500528A1 (en) 2021-06-07
AU2018354370A1 (en) 2020-04-09
CL2020001090A1 (es) 2020-08-21
IL274037B2 (en) 2023-11-01
HRP20221221T1 (hr) 2022-12-09
EA202091016A1 (ru) 2020-07-17
AR113803A1 (es) 2020-06-10
US20210214349A1 (en) 2021-07-15
CU20200053A7 (es) 2021-03-11
KR102613503B1 (ko) 2023-12-13
MX2020004255A (es) 2020-07-29
SI3672965T1 (sl) 2022-11-30
JP7218364B2 (ja) 2023-02-06
US20240158389A1 (en) 2024-05-16
CN111247142A (zh) 2020-06-05
CU24671B1 (es) 2023-07-12
GEAP202115340A (en) 2021-08-10
GEP20227344B (en) 2022-01-25
HUE060401T2 (hu) 2023-02-28
IL274037A (en) 2020-06-30
CR20200180A (es) 2020-08-12
DK3672965T3 (da) 2022-10-03
AU2018354370B2 (en) 2023-04-27
IL274037B1 (en) 2023-07-01
CN111247142B (zh) 2022-12-02
BR112020008015A2 (pt) 2020-10-27
ECSP20023795A (es) 2020-06-30
SG11202001706RA (en) 2020-03-30
UA125130C2 (uk) 2022-01-12
LT3672965T (lt) 2022-10-10
ES2932526T3 (es) 2023-01-20
JP2021501151A (ja) 2021-01-14
US10774080B2 (en) 2020-09-15
MA49956A (fr) 2020-07-01
US20190241555A1 (en) 2019-08-08
US10562894B2 (en) 2020-02-18
US11814377B2 (en) 2023-11-14
EP3672965A1 (en) 2020-07-01
SMT202200409T1 (it) 2022-11-18
US10308646B2 (en) 2019-06-04
US11420965B2 (en) 2022-08-23
MD3672965T2 (ro) 2022-12-31
DOP2020000083A (es) 2020-08-15
TW201930304A (zh) 2019-08-01
US20220396573A1 (en) 2022-12-15
KR20200078517A (ko) 2020-07-01
NI202000032A (es) 2020-10-09
US20200140430A1 (en) 2020-05-07
CA3074034A1 (en) 2019-05-02
WO2019084383A1 (en) 2019-05-02
TWI789446B (zh) 2023-01-11
US12172994B2 (en) 2024-12-24
PL3672965T3 (pl) 2023-01-16
RS63608B1 (sr) 2022-10-31

Similar Documents

Publication Publication Date Title
PE20201495A1 (es) Compuesto de pirimidina como inhibidor de las janocinasas
UY37927A (es) Proceso para la preparación de 6-(2-hidroxi-2-metilpropoxi)-4-(6-(6-((6-metoxipiridin-3-il)metil)-3,6-diazabiciclo[3.1.1]heptan-3-il)piridin-3-il)pirazolo[1,5-a]piridina-3-carbonitrilo
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
EP4248988A3 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
MX2015018048A (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
PH12018501073A1 (en) Eif4-a-inhibiting compounds and methods related thereto
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
BR112012029647A2 (pt) novos derivados de pirimidinas
WO2011117145A3 (en) Pyrrolopyrazine kinase inhibitors
UY32648A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de enfermedades
NZ705040A (en) Fused pyrimidines as inhibitors of p97 complex
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
MX2016001845A (es) Compuesto novedoso de pirimidina fusionada o sal del mismo.
GEP201706748B (en) Heteroaromatic compounds as bruton&#39;s tyrosine kinase (btk) inhibitors
MX2016006336A (es) Compuestos pirazolopirimidina.
MX2011008583A (es) Pirimidinas fusionadas.
PH12012501631A1 (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
PH12015501585A1 (en) Manufacturing process for pyrimidine derivatives
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2013010898A (es) Novedoso derivados de la pirimidina.
PH12012501630A1 (en) Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd
EA201600337A1 (ru) 2,6-замещенные пуриновые производные и их применение в лечении пролиферативных заболеваний
MX395263B (es) Forma cristalina de base libre de lorlatinib